8-K: Dare Bioscience to Launch Sildenafil Cream via 503B Compounding, Announces 2024 Financial Results

Dare Bioscience plans to make its proprietary Sildenafil Cream formulation available via prescription this year through 503B compounding, while also reporting its financial results for the year ended December 31, 2024.

Summary

• Dare Bioscience reported its financial results for the year ended December 31, 2024.
• The company plans to make its proprietary Sildenafil Cream formulation available via prescription this year through 503B compounding.
• Dare expects to start recording revenue and cash flow from Sildenafil Cream in the fourth quarter of 2025.
• The company's cash and cash equivalents were approximately $15.7 million as of December 31, 2024.
• General and administrative expenses decreased by 24% to approximately $9.2 million for 2024.
• Research and development expenses decreased by 34% to approximately $14.2 million for 2024.
• The company is progressing with its Phase 3 study of Ovaprene, with interim data review expected by the end of the second quarter of 2025.
• Dare is also conducting activities to enable submission of an IND application for DARE-HPV and preparing for a Phase 2 clinical study of DARE-VVA1.
• The company received $3.5 million in grant funding for DARE-LARC1 in 2024, bringing the total received to date to $31.8 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is launching a product via 503B compounding, which is a positive step towards revenue generation. The decrease in expenses is also a positive sign. However, the company still has a net loss and a working capital deficit, which tempers the overall sentiment.

Positives

• The company is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year as a compounded drug under Section 503B of the FDCA.
• Dare expects to start recording revenue and cash flow in the 4th quarter of this year from Sildenafil Cream.
• General and administrative expenses decreased by 24% compared to the prior year.
• Research and development expenses decreased by 34% compared to the prior year.
• The company received an up to $10.7 million foundation non-dilutive grant to support the addition of 5 new investigator sites for Ovaprene.
• Dare entered into a co-development and licensing agreement with Theramex for the development of Casea S in the U.S.

Negatives

• The company reported a net loss of $4,053,299 for the year ended December 31, 2024.
• The company had a working capital deficit of approximately $3.2 million as of December 31, 2024.

Risks

• The company's ability to raise additional capital when and as needed to advance its product candidates and continue as a going concern.
• The risk of delisting of the company's common stock from Nasdaq.
• The degree of market demand and acceptance for the company's proprietary formulation of Sildenafil Cream provided as a compounded drug.
• The company's reliance on third parties to manufacture and conduct clinical trials and preclinical studies of its product candidates.
• The risk that the FDA could stop permitting Section 503B-registered outsourcing facilities to compound sildenafil citrate.
• The company's ability to achieve the product development and other milestones required for it to receive payments under its subaward and grant agreements.
• The company's ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines.
• Failure or delay in starting, conducting and completing clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials.
• The company's dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product.
• The risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate.
• The risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with the company's interpretation of or conclusions regarding data from clinical studies of its product candidates.
• The risk that development of a product candidate requires more clinical or nonclinical studies than the company anticipates.
• The loss of, or inability to attract, key personnel.
• The effects of macroeconomic conditions, geopolitical events, public health emergencies, and major disruptions in government operations on the company's operations, financial results and condition, and ability to achieve current plans and objectives.
• The risk that developments by competitors make the company's product or product candidates less competitive or obsolete.
• Difficulties establishing and sustaining relationships with development and/or commercial collaborators.
• Failure of the company's product or product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors.
• The company's ability to retain its licensed rights to develop and commercialize a product or product candidate.
• The company's ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates.
• The company's ability to adequately protect or enforce its, or its licensors, intellectual property rights.
• The lack of patent protection for the active ingredients in certain of the company's product candidates which could expose its products to competition from other formulations using the same active ingredients.
• Product liability claims.
• Governmental investigations or actions relating to the company's product or product candidates or the business activities of the company, its commercial collaborators or other third parties on which the company relies.
• The impact of pharmaceutical industry regulation and health care legislation in the United States and internationally.
• Global trends toward health care cost containment.
• Cybersecurity incidents or similar events that compromise the company's technology systems or those of third parties on which it relies and/or significantly disrupt the company's business.
• Disputes or other developments concerning the company's intellectual property rights.

Future Outlook

Dare Bioscience anticipates meaningful milestones in 2025, driven by its diverse portfolio, progress in advancing product candidates, and the revenue opportunity from its proprietary Sildenafil Cream formulation. The company expects to start recording revenue and cash flow from Sildenafil Cream in the fourth quarter of 2025. They are also targeting the second quarter of 2025 to provide an update on strategic partnerships.

Management Comments

• Sabrina Martucci Johnson, President and CEO of Dar Bioscience, stated that the company is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year as a compounded drug under Section 503B of the FDCA.
• Ms. Johnson believes the diversity of the portfolio, the progress being made in advancing product candidates, and the revenue opportunity from the proprietary Sildenafil Cream formulation puts Dar on track for meaningful milestones in 2025.
• Ms. Johnson added that the company plans to focus its resources on provider-to-provider education about disease state and its proprietary formulation and does not anticipate needing to invest more than $1 million to support the activities required to make its Sildenafil Cream formulation available via a partner 503B-registered outsourcing facility.

Industry Context

Dare Bioscience's focus on women's health addresses a historically underserved market. The company's strategy of leveraging existing safety data and clinical proof of concept for its product candidates aligns with a trend towards efficient drug development. The decision to pursue 503B compounding for Sildenafil Cream reflects a growing interest in alternative regulatory pathways to bring treatments to market more quickly.

Comparison to Industry Standards

• The decision to pursue 503B compounding for Sildenafil Cream is a strategic move to generate revenue while navigating the traditional FDA approval process, similar to how some companies in the pharmaceutical industry use early access programs or compassionate use pathways.
• The company's focus on women's health is in line with a growing trend in the biopharmaceutical industry to address unmet needs in this area, with companies like Organon also focusing on women's health products.
• The company's approach of leveraging existing safety data and clinical proof of concept for its product candidates is similar to the strategy employed by other companies in the industry to reduce development costs and timelines.

Stakeholder Impact

• Shareholders can anticipate potential revenue generation from Sildenafil Cream in the near term.
• Healthcare providers will have access to a new treatment option for female sexual arousal disorder.
• Women will have access to a compounded formulation of Sildenafil Cream via prescription.

Next Steps

• Dare will focus its resources on provider-to-provider education about disease state and its proprietary formulation.
• The company plans to submit the protocol and statistical analysis plan for an adequate and well-controlled Phase 3 clinical study, reflecting the FDA's recommendations, to the FDA in the second quarter of 2025.
• Dare is targeting the second quarter of 2025 to provide an update on the strategic partnerships to achieve these objectives.
• The company expects to start recording revenue and cash flow in the 4th quarter of this year.

Key Dates

Keywords

Sildenafil Cream, Ovaprene, womens health, 503B compounding, clinical trials, financial results, Dare Bioscience, DARE-HPV, DARE-VVA1, DARE-LARC1, Casea S, contraception, FSAD